MSSA and Ceftriaxone Etest issue: CLSI & ASM White Paper
The data presented in a now-retracted report were obtained using Etest Ceftriaxone strips, which are not FDA-cleared for testing of staphylococci. The white paper addresses the need for reference confirmatory testing of any new resistance seen. Current CLSI M100 guidance stating that oxacillin (cefoxitin) testing can be used for predicting the susceptibility of staphylococci to ceftriaxone can and should be used. To read the paper in its entirety, click here.